Immunotherapy for Ph-adult acute lymphoblastic leukemia: reports from the 56th American Society of Hematology annual meeting / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
;
(12): 23-26, 2015.
Artigo
em Chinês
| WPRIM
| ID: wpr-465867
ABSTRACT
Outcome of patients with adult acute lymphoblastic leukemia (ALL) is poor,and even worse among patients with relapsed/refractory ALL (R/R ALL).New treatments must be taken to overcome drugresistance to conventional chemotherapy for ALL.Humanized monoclonal antibody and chimeric antigen receptor gene modified T cells have become the focus of treatment in ALL.Lots of clinical trials in multiple research centers are in progress,and the results constantly upgrade which is effectively bring better curative effect and prognosis for R/R ALL patients.This is one of the hot topics at the 56th ASH annual meeting.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Leukemia & Lymphoma
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS